The response to vitamin K antagonists (VKAs) is determined by many different factors like age, weight, height, vitamin K intake and genetic polymorphisms [1]. The proton pump inhibitors (PPIs) omeprazole and esomeprazole may enhance the effect of VKAs by inhibition of the hepatic metabolism of coumarins [2]. Some isolated cases have been reported of clinically significant elevated INRs in patients concomitantly using omeprazole and phenprocoumon, a VKA frequently used in Europe [3].Practical experience suggests an interaction between omeprazole or esomeprazole and phenprocoumon, but scientific evidence is still lacking.

, , , , ,
doi.org/10.1111/j.1365-2125.2012.04295.x, hdl.handle.net/1765/38381
British Journal of Clinical Pharmacology
Erasmus School of Health Policy & Management (ESHPM)

Verhoef, T., Zuurhout, M. J. L., van Schie, R., Redekop, K., van der Meer, F., le Cessie, S., … Maitland-van der Zee, A.-H. (2012). The effect of omeprazole and esomeprazole on the maintenance dose of phenprocoumon. British Journal of Clinical Pharmacology, 74(6), 1068–1069. doi:10.1111/j.1365-2125.2012.04295.x